Clinical impact of immunotherapy

Chair: Poulam Patel, University of Nottingham, UK
Speaker: James Larkin, Royal Marsden NHS Foundation Trust, UK
Speaker: Paul Nathan, Mount Vernon Hospital, UK
Speaker: Mary O'Brien, Royal Marsden Hospital, UK


Room: Alsh

Immunotherapy is revolutionising our approach to treating cancer. In some cancer such as melanoma, it has transformed the survival of many patients from a few months to many years and possible cure. These advances are now part of standard of care more common cancers such as lung and urological cancer. This however, comes with new range of toxicities not previously seen with anti-cancer therapies. These developments come with significant opportunities but also challenges.

This session will outline the key clinical developments in immunotherapy focusing on melanoma and lung cancer as exemplars and discuss the treatment of immune related side effects.